Insights into the Suppression of Multidrug-Resistant Helicobacter pylori by Probiotics Supernatant

 The eradication of multidrug-resistant Helicobacter pylori has become a major problem for medical care.

 In this study, the probiotics supernatant against drug-resistant H. pylori has been investigated.

 First, the antimicrobial susceptibilities of the six H. pylori isolated from patients were determined by E-test. Second, Lactobacillus isolates with anti-H. pylori were activity isolated from healthy baby feces in order to inhibit the growth of H. pylori HP3. Furthermore, physical and chemical properties of antimicrobial fraction S18 and the viability of Lactobacillus reuteri S18 were investigated in simulated gastric fluid and simulated intestinal fluid.

 Multidrug-resistant H. pylori HP3 isolates showing four typical antibiotic resistances were selected for further study in which Lactobacillus isolates inhibited the growth of the H. pylori HP3 by producing lactate and acetic acid, and its anti-H. pylori activity disappeared after the neutralization of pH. Lactobacillus reuteri S18 with an inhibitory value (∼75%) were selected as a fighter against H. pylori HP3. Antimicrobial fraction S18 from L. reuteri S18 is stable in pepsin and is inactivated by trypsin, lysozyme and protease K. In the end, it was observed that the growth of H. pylori HP3 was completely suppressed by the antimicrobial fraction S18 at a working time of 8 h. Moreover, the cell viability of L. reuteri S18 was decreased by 20.8% and 62.5% after treatment in simulated gastric fluid and simulated intestinal fluid, respectively. Lactobacillus reuteri S18 can survive in the stomach (acidic environment) fighting for the H. pylori HP3, which can be suppressed in the intestine subsequently.

 Lactobacillus reuteri S18 holds the potential to be applied to medical care against multidrug-resistant H. pylori.